AstraZeneca PLC's strategy of offloading mature brands to boost reinvestment into its pipeline is picking up speed again with the sale of commercial rights to cancer drugs Arimidex and Casodex in a number of European, African and other countries to France's Juvisé Pharmaceuticals.
AZ Divests Arimidex And Casodex Rights To Juvisé
Banks Upfront Payment Of $181m
Selling off the two cancer drugs to the French firm is the latest example of AstraZeneca's strategy of reducing its portfolio of mature assets to boost its R&D budget.
More from Deals
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
More from Business
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.